Fame and Mortality: Evidence from a Retrospective Analysis of Singers
November 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Gomekli
Synonyms :
Mirdametinib
Class :
Antineoplastics, MEK Inhibitors
Brand Name :
Gomekli
Synonyms :
Mirdametinib
Class :
Antineoplastics, MEK Inhibitors
Dosage forms & Strengths:
Adult
Neurofibromatosis Type 1 (NF1)
Pediatric
Neurofibromatosis Type 1 (NF1)
Refer as per adult dose
Mirdametinib is a MEK inhibitor that targets MEK1 and MEK2 prevents MAP kinase phosphorylation and activation.
Neurofibromatosis type 1 is a rare genetic disorder caused by NF1 gene mutations affects neurofibromin.
NF1 patients may develop plexiform neurofibromas to cause disfigurement, pain, and impaired function along peripheral nerves.
Frequency not defined:
Rash
Diarrhea
Nausea
Musculoskeletal pain
Vomiting, and fatigue
Abdominal pain
Vomiting
Headache
Paronychia
Left ventricular dysfunction
None
Contraindication:
Hypersensitivity
Caution:
Ocular toxicity
Left ventricular dysfunction
dermatologic adverse reactions
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Mirdametinib inhibits MEK1/2 to upstream regulators of the ERK pathway in cellular signalling.
It inhibits MEK1/MEK2 kinase activity, and ERK phosphorylation to reduce neurofibroma tumor volume and proliferation in NF1 mouse models.
Pharmacodynamics This FDA approved drug based on the Phase 2b ReNeu trial involves 58 adults and 56 pediatric NF1-PN patients, demonstrating strong response rates, significant tumor reductions, and manageable safety.
Plexiform neurofibromas may become aggressive and fatal malignant tumors.
Pharmacokinetics Data is not available on ADME.
As per available information it is administered through oral route.
mirdametinib
Why do we use mirdametinib?
Mirdametinib is indicated for treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN).
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
